MitoRx Therapeutics is pioneering a novel class of mitochondrial-targeted therapeutics designed to restore sulfide-mediated protective metabolism, particularly in conditions such as obesity-related diseases and myopathies. Their innovative mtH2SD technology focuses on addressing mitochondrial dysfunction by utilizing mitochondrial-targeted sulfide donors. This approach aims to reverse trans-sulfuration deficiencies that are implicated in various progressive metabolic diseases, muscle weakness, and neurodegenerative disorders. The technology is built on over a decade of research, demonstrating the pharmacological utility of these sulfide donors in multiple in vivo models, thereby establishing a strong foundation for their therapeutic potential.

The mechanism of action for MitoRx's therapeutics involves the restoration of mitochondrial function through the modulation of key metabolic transactivators, which are often under-activated in target diseases. By enabling safe enzymatic release of hydrogen sulfide (H₂S) within the mitochondria, the mtH2SD technology replenishes essential substrates required for protein S-persulfidation, thereby reinstating sulfide-signaling pathways crucial for adaptive metabolism. This restoration is expected to halt or reverse disease progression in a range of conditions, including Duchenne muscular dystrophy, lung inflammatory diseases, and neurodegenerative disorders such as Parkinson's and Alzheimer's diseases. MitoRx's commitment to developing these first-in-class therapeutics positions them at the forefront of addressing mitochondrial dysfunction in various medical fields.

United Kingdom

MitoRx Therapeutics is a pre-clinical stage rare disease biotech company aiming to become the leading global developer of medicines arresting the progression of degenerative diseases driven by mitochondrial dysfunction, with a focus on neuromuscular disease, metabolic disease and neurodegenerative disease. 

MitoRx Therapeutics

Company Details